ERBB2 and breast cancer: To confirm the validity of our proteomic findings and strengthen their potential utility and translation toward clinical applications, we next sought to verify the trends in EV signature proteins in circulating EVs derived from a small cohort of TNBC- and HER2-positive breast cancer patient serum samples (five patients per subtype).